Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography
Authors:
- 29 February 2008
- journal article
- research article
- Published by Springer Nature in Skeletal Radiology
- Vol. 37 (5) , 415-421
Abstract
To evaluate the efficacy of F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG PET/CT) in differentiating malignant from benign pathologic fractures.Keywords
This publication has 17 references indexed in Scilit:
- F-18 FDG PET/CT Evaluation of Osseous and Soft Tissue SarcomasClinical Nuclear Medicine, 2006
- PET/CT in the Evaluation of Childhood SarcomasAmerican Journal of Roentgenology, 2005
- FDG-PET uptake in occult acute pelvic fractureSkeletal Radiology, 2004
- Rapid normalization of osseous FDG uptake following traumatic or surgical fracturesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Utility of FDG-PET in differential diagnosis of benign and malignant fractures in acute to subacute phaseAnnals of Nuclear Medicine, 2003
- Molecular imaging of cancer with positron emission tomographyNature Reviews Cancer, 2002
- FDG PET of Primary Benign and Malignant Bone Tumors: Standardized Uptake Value in 52 LesionsRadiology, 2001
- Clinical Value of [18-F] Fluorodeoxyglucose Positron Emission Tomography Imaging in Soft Tissue SarcomasAnnals of Surgery, 2000
- Increased F-18 FDG Accumulation in an Acute FractureClinical Nuclear Medicine, 1994
- F-18 Fluorodeoxyglucose: Its Potential in Differentiating Between Stress Fracture and NeoplasiaClinical Nuclear Medicine, 1989